Celldex Therapeutics (CLDX) Income towards Parent Company (2010 - 2026)

Celldex Therapeutics' Income towards Parent Company history runs 17 years deep, the most recent figure standing at -$85.9 million for Q1 2026.

• In Q1 2026, Income towards Parent Company fell 37.12% year-over-year to -$85.9 million; the TTM figure through Mar 2026 stood at -$326.8 million (up 34.59% YoY), while the FY2025 annual figure was -$661.6 million, down 38.51% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$85.9 million, up from -$109.6 million in the prior quarter.
• The five-year high for Income towards Parent Company was -$23.0 million in Q1 2022, with the low at -$390.7 million in Q4 2023.
• The 5-year median for Income towards Parent Company is -$47.7 million (2024), against an average of -$87.0 million.
• The sharpest annual moves came in 2023 and 2025: Income towards Parent Company slumped 1375.03% in 2023, then jumped 67.81% in 2025.
• Celldex Therapeutics' Income towards Parent Company stood at -$26.5 million in 2022, then plunged by 1375.03% to -$390.7 million in 2023, then increased by 12.83% to -$340.5 million in 2024, then surged by 67.81% to -$109.6 million in 2025, then grew by 21.63% to -$85.9 million in 2026.
• Business Quant data shows CLDX's Income towards Parent Company at -$85.9 million in Q1 2026, -$109.6 million in Q4 2025, and -$67.0 million in Q3 2025.